Status:
COMPLETED
A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks
Lead Sponsor:
Beth Israel Medical Center
Conditions:
Major Depression With Panic Attacks
Panic Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This study compares the efficacy of risperidone to that of paroxetine in the treatment of panic attacks in patients with Panic Disorder and with Major Depressive Disorder with Panic attacks and compar...
Detailed Description
Rationale Risperidone is an atypical antipsychotic drug that acts as an antagonist at 5-HT2A/2C and D2 receptors (Chouignard et al, 1993; Marder \& Meibach, 1994). In its serotonergic activity, rispe...
Eligibility Criteria
Inclusion
- Males and females, ages 18-55.
- Ability to sign an informed consent
- Diagnosis of Panic Disorder, or MDD with Panic attacks, single episode, recurrent, or chronic
- HAM-A score \>17
Exclusion
- Alcohol or substance abuse within the last 6 months
- Current diagnosis of Obsessive-Compulsive Disorder
- Current diagnosis of Schizophrenia, Schizoaffective Disorder, or Bipolar Mood Disorder
- Use of antipsychotic medications over the two months preceding enrollment in the study
- Changes in antidepressant or mood stabilizer dosing over the two months preceding enrollment in the study
- Previous adverse reaction to risperidone or paroxetine.
Key Trial Info
Start Date :
June 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2003
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00457106
Start Date
June 1 2002
End Date
June 1 2003
Last Update
December 1 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Medical Center
New York, New York, United States, 10003